Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
Ajai Chari, MD, discusses a study finding that the novel bispecific antibody talquetamab produced responses in more than 70 percent of heavily pretreated patients with multiple myeloma.
Press Release
Unprecedented Therapy Found Effective for Blood Cancer Patients With No Treatment Options
Aug 22, 2019 View All Press Releases